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Mannheimia haemolytica isolated from feedlot cattle were tested for tulathromycin
resistance. Cattle were sampled over a 3-year period, starting 12 months after approval of
tulathromycin for prevention and treatment of bovine respiratory disease. Nasopharyngeal
samples from approximately 5,814 cattle were collected when cattle entered feedlots
(N = 4) and again from the same cattle after ≥60 days on feed. The antimicrobial use
history for each animal was recorded. Mannheimia haemolytica was isolated from 796
(13.7%) entry samples and 1,038 (20.6%) ≥ 60 days samples. Of the cattle positive
for M. haemolytica, 18.5, 2.9, and 2.4% were administered therapeutic concentrations
of tulathromycin, tilmicosin, or tylosin tartrate, respectively. In addition, 13.2% were
administered subtherapeutic concentrations of tylosin phosphate in feed. In years one
and two, no tulathromycin-resistant M. haemolytica were detected, whereas ﬁve isolates
(0.4%) were resistant in year three. These resistant isolates were collected from three
cattle originating from a single pen, were all serotype 1, andwere genetically related (≥89%
similarity) according to pulsed-ﬁeld gel electrophoreses patterns. The ﬁve tulathromycin-
resistant isolates were multi-drug resistant also exhibiting resistance to oxytetracycline,
tilmicosin, ampicillin, or penicillin.Themacrolide resistance genes erm(42), erm(A), erm(B),
erm(F), erm(X) and msr (E)-mph(E), were not detected in the tulathromycin-resistant M.
haemolytica. This study showed that tulathromycin resistance in M. haemolytica from a
general population of feedlot cattle in western Canada was low and did not change over a
3-year period after tulathromycin was approved for use in cattle.
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INTRODUCTION
Bovine respiratory disease (BRD) continues to be a health issue
for feedlots in North America. The disease results in direct eco-
nomic losses due to morbidity and mortalities and indirect losses
resulting from reduced feed efﬁciency and meat quality (Duff and
Galyean, 2007). Cattle exhibiting signs of BRD can be infected
by more than one causative agent, but Mannheimia haemolyt-
ica is consistently detected as the primary bacterial agent of BRD
(Zecchinon et al., 2005). In feedlots, BRD is primarily managed
through administration of vaccines and antimicrobial agents. Vac-
cination is typically for viruses and to a lesser extent, for bacteria
such asM. haemolytica, although efﬁcacy has been variable (Larson
and Step, 2012). In contrast, antimicrobial agents such as ceftio-
fur, ﬂorfenicol, tulathromycin, and tilmicosin have been shown to
reduce morbidity when used metaphylactically on high-risk cattle
entering feedlots (Taylor et al., 2010).
Macrolides are used extensively in feedlot production systems
at subtherapeutic concentrations to promote growth and ther-
apeutic concentrations to treat or prevent bacterial infections,
including those that are BRD-associated (Marshall and Levy,
2011). Macrolides consist of a core macrolactone ring that binds
to the large subunit of the ribosome and blocks bacterial pro-
tein synthesis (Poehlsgaard and Douthwaite, 2005). Differences in
the ring structure can affect pharmacokinetic/pharmacodynamic
properties and have been the basis for the development of
new macrolide derivatives over the years (Godinho, 2008).
Tulathromycin is a macrolide that has three amine rings and is
further sub-classiﬁed as a triamilide. In 2006, tulathromycin was
approved for use in Canada to treat and prevent BRD in high-risk
cattle entering feedlots (Schunicht et al., 2007). Compared to other
antimicrobial agents, tulathromycin has been shown to be equiv-
alent or more efﬁcacious in therapeutic treatment of feedlot cattle
displaying BRD (Nutsch et al., 2005; Skogerboe et al., 2005) and
in preventing cases of BRD after metaphylactic administration to
high-risk cattle (Booker et al., 2007;Van Donkersgoed et al., 2008).
Consequently it has become widely used by the feedlot industry.
Recent studies have characterized genes in M. haemolytica that
provide cross-resistance to tulathromycin and other macrolides
(Desmolaize et al., 2011; Michael et al., 2012a; Rose et al., 2012).
Resistance to antibiotics commonly used for BRD poses animal
health and economic concerns. Despite this, few epidemiologi-
cal studies have been conducted in North America to monitor
macrolide resistance in veterinary pathogens. We have previously
shown macrolide resistance to be low in M. haemolytica isolated
from randomly selected feedlot cattle, although in this study iso-
lates were collected over a short period of time (Klima et al.,
2011). In a multi-year study, it was reported that susceptibility
to tulathromycin and tilmicosin decreased over a 5-year period in
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M. haemolytica isolated fromdiseased or deceased cattle in Canada
and theUnited States (Portis et al., 2012). However, animal history,
including antimicrobial use, was not reported and isolates from
healthy cattle were not included in the analysis (Portis et al., 2012).
The purpose of the current study was to evaluate tulathromycin
resistance in M. haemolytica isolated from cattle with a known
history of antimicrobial use over a 3-year period.
MATERIALS AND METHODS
ANIMALS
As part of a longitudinal surveillance study monitoring resis-
tance in bovine fecal and respiratory bacteria (Klima et al., 2011;
Alexander et al., 2013), M. haemolytica were isolated from feedlot
cattle with a known history of antimicrobial use. Nasopharyngeal
samples were collected from cattle at four commercial feedlots
in southern Alberta, Canada between September, 2007 and May,
2010. A subset of cattle (a random selection of approximately 10%
of animals from 30% of feedlot pens) housed within the feedlots
were enrolled in the study. The cattle were sampled upon entry
into feedlots and again after ≥60 days on feed. In total, 5,814
cattle were enrolled in the study. Antimicrobial administration
was recorded for all cattle, as described previously (Klima et al.,
2011). Sampling took place from September, 2007 to August, 2008
(year 1), September, 2008 to August, 2009 (year 2), and Septem-
ber, 2009 to May, 2010 (year 3). These dates correspond to 2, 3,
and 4 years after tulathromycin was approved for use in Canada
(Health Canada, 2006).
BACTERIAL ISOLATION
Double guarded nasal swabs were used to sample the nasophar-
ynx of cattle. Swabs were stored in Cary Blair transport medium
(BD Canada, Inc., Mississauga, ON, Canada) at 4◦C prior to pro-
cessing, as described by Klima et al. (2011). Brieﬂy, swabs were
vortexed in 0.7 mL of brain heart infusion (BHI) broth, and a
100-μL aliquot of the suspension was cultured on tryptic soy
agar (TSA) plates containing 5% sheep blood and 15 μg/mL
of bacitracin (Dalynn Biologicals, Inc., Calgary, AB, Canada) at
37◦C for 24 h (Catry et al., 2006). Isolates displaying morphol-
ogy indicative of Mannheimia were subcultured (conditions as
above) from each plate and tested for catalase and oxidase. Iso-
lates with the typical colony morphology and that were both
catalase and oxidase positive were tentatively identiﬁed as M.
haemolytica. Identity was conﬁrmed using a multiplex PCR assay
(Alexander et al., 2008). Up to three conﬁrmed isolates from each
positive animal were stored at −80◦C in BHI broth containing
20% glycerol.
ANTIMICROBIAL SUSCEPTIBILITY
Isolates of M. haemolytica (N = 4,548) were screened for
tulathromycin susceptibility by plating onto BHI plates supple-
mented with 2 μg/mL tulathromycin, followed by incubation at
37◦C for 24 h. A concentration of 2◦μg/mLwas selected based on a
previous study reporting 97% of bovine M. haemolytica ﬁeld iso-
lates having tulathromycin minimum inhibitory concentrations
(MICs) of ≤2 μg/mL (Godinho, 2008). Tulathromycin was kindly
provided by Pﬁzer Animal Health (now Zoetis) and prepared
according to the manufacturer’s instructions. Isolates that grew
on tulathromycin-supplemented BHI plates were further tested
for antimicrobial susceptibility using a commercially available
broth microdilution panel (Bovine/Porcine with Tulathromycin
MIC Format, Sensititre; Trek Diagnostic Systems, Cleveland, OH,
USA). A list of the antimicrobial agents utilized and the range
of concentrations tested are presented in Table 1. In addition
to these, sulphadimethoxine and trimethoprim/sulfamethoxazole
were included in the panel at single breakpoint concentrations of
256 and 2/38 μg/mL, respectively. Bacterial growth was assessed
by visual assessment and MICs were deﬁned according to recom-
mendations provided in the Clinical and Laboratory Standards
Institute document M31-A3 (CLSI, 2008). Clinical and Labora-
tory Standards breakpoints were not available for clindamycin,
neomycin, penicillin, tiamulin, sulphadimethoxine, trimetho-
prim/sulfamethoxazole or tylosin tartrate. Therefore, susceptibil-
ity designations for these drugs were not assigned. Exceptions to
this are cases where isolates exhibited a high MIC for neomycin
(MIC 32 μg/ml) or penicillin (MIC 8 μg/ml) and harbored
the corresponding resistance determinant, aphA-1 or blaROB−1,
respectively.
PCR DETECTION OF ANTIMICROBIAL RESISTANCE GENES
Isolates of M. haemolytica that grew on BHI plates supplemented
with 2 μg/mL of tulathromycin were analyzed for resistance genes
using PCR. A description of genes, primers, and annealing tem-
peratures are found in Table 2. Colonies of M. haemolytica were
Table 1 |The MICs of M. haemolytica isolated from the nasopharynx of
feedlot cattlea
Antibiotic (concentrations tested,
μg/mL)
Isolate
32A 32B 32C 50A 55A
Ampicillin (0.25, 0.5, 1, 2, 4, 8, 16*) 0.25 0.25 0.25 0.25 >16
Ceftiofur (0.25, 0.5, 1, 2, 4, 8b) 0.25 0.25 0.25 0.25 0.5
Chlortetracycline (0.5, 1, 2, 4, 8) 4 4 2 2 2
Clindamycin (0.25, 0.5, 1, 2, 4, 8, 16) 16 16 16 16 16
Danoﬂoxacin (0.12, 0.25b, 0.5, 1) 0.12 0.12 0.12 0.12 0.12
Enroﬂoxacin (0.12, 0.25, 0.5, 1, 2b) 0.12 0.12 0.12 0.12 0.12
Florfenicol (0.25, 0.5, 1, 2, 4, 8b) 1 1 1 1 0.5
Gentamycin (1, 2, 4, 8, 16) 2 2 2 2 2
Neomycin (4, 8, 16, 32*) >32 >32 >32 >32 >32
Oxytetracycline (0.5, 1, 2, 4, 8b) >8 >8 >8 >8 >8
Penicillin (0.12, 0.25, 0.5, 1, 2, 4, 8*) 0.12 0.12 0.25 0.25 >8
Spectinomycin (8, 16, 32, 64) 32 32 32 32 32
Tiamulin (0.5, 1, 2, 4, 8, 16, 32) 32 32 32 32 16
Tilmicosin (4, 8, 16, 32b, 64) 64 64 64 >64 >64
Tulathromycin (1, 2, 4, 8, 16, 32, 64b) 64 64 64 64 64
Tylosin tartrate 0.5, 1, 2, 4, 8, 16, 32) >32 >32 >32 >32 >32
aIsolates were ﬁrst screened for reduced tulathromycin susceptibility by culturing
onto BHI plates supplemented with tulathromycin (2 μg/mL).
bBreakpoints deﬁning resistance (CLSI, 2008).
*Resistance breakpoint deﬁned by authors.
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Table 2 | Primers used to screen for antimicrobial resistance genes in M. haemolytica isolated from feedlot cattle.
Resistance phenotypea Resistance gene Primer sequences 5′–3′ Annealing (◦C) Reference
Amp, Pen blaROB−1 AATAACCCTTGCCCCAATTC 60 Klima et al. (2011)
TCGCTTATCAGGTGTGCTTG
Neo aphA-1 TTATGCCTCTTCCGACCATC 54 Klima et al. (2013)
GAGAAAACTCACCGAGGCAG
Tet tet(H) ATACTGCTGATCACCGT 60 Klima et al. (2011)
TCCCAATAAGCGACGCT
Til, Tul erm(A) GAAATYGGRTCAGGAAAAGG 55 Chen et al. (2007)
AAYAGYAAACCYAAAGCTC
erm(B) GATACCGTTTACGAAATTGG 58 Chen et al. (2007)
GAATCGAGACTTGAGTGTGC
erm(F) CGACACAGCTTTGGTTGAAC 56 Chen et al. (2007)
GGACCTACCTCATAGACAAG
erm(X) GAGATCGGRCCAGGAAGC 58 Chen et al. (2007)
GTGTGCACCATCGCCTGA
erm(42) GGGTGAAAAGGGCGTTTATT 60 Kadlec et al. (2011)
ACGTTGCACTTGGTTTGACA
msr (E)-mph(E) TACCGGAACAACGTGATTGA 60 Kadlec et al. (2011)
GAAGGGTTACGCCAGTACCA
aAmp, ampicillin; Neo, neomycin; Pen, penicillin; Tet, tetracycline; Til, tilmicosin; Tul, tulathromycin.
heat lysed (98◦C for 4 min) and centrifuged (16,000 × g ; 4 min),
and the supernatant (1 μL) was added to the PCR mixture as
DNA template. PCRwere performed using 1×QiagenHotStarTaq
Plus Master Mix (Qiagen Inc.) on a MasterCycler thermal cycler
(Eppendorf). Twenty microliters of product was visualized on a
1.5% (wt/vol) agarose gel following electrophoresis and staining
with ethidium bromide. All PCR were run with positive controls
(plasmids with sequence-veriﬁed genes) for respective gene deter-
minants and negative controls containing water in place of a DNA
template.
SEROTYPING AND PULSED-FIELD GEL ELECTROPHORESIS
Mannheimia haemolytica that grew on BHI plates supplemented
with 2 μg/mL of tulathromycin were further characterized by
serotyping and PFGE. Serotyping was performed using the rapid
plate agglutination procedure as described by Frank and Wess-
man (1978). For PFGE, macro-restriction digest was performed
according to Klima et al. (2010), using SalI (New England Biolabs)
restriction enzyme.
RESULTS
ISOLATION OF MANNHEIMIA HAEMOLYTICA AND ADMINISTRATION
OF MACROLIDE ANTIMICROBIAL AGENTS
A total of 5,814 cattle were enrolled in the study and sampled
upon entry into feedlots (Table 3). Of these, 5,036 were sampled
a second time after ≥60 days on feed. M. haemolytica was isolated
from796 (13.7%) to 1,038 (20.6%) of entry and≥60 days samples,
respectively. In total, 1,688 cattle were positive for M. haemolytica
at entry, ≥60 days on feed, or at both samplings. Of the cattle
positive for M. haemolytica upon entry, only 146 were positive at
the second sampling. There were 403, 821, and 464 cattle positive
forM.haemolytica during years 1, 2, and 3 of the study, respectively
(Table 4). From these cattle, 862, 2,342, and 1,344 M. haemolytica
isolates were isolated in years 1–3 (Table 4).
Table 3 | History of macrolide use in feedlot cattle that were positive
for M. haemolytica over a 3-year period.
Number of cattlea
Entry ≥60 dayson feed Total
Cattle sampled 5,814 5,036 10,850
Positive for M. haemolytica 796 1,038 1,834
Administered tulathromycinb 259 53 312
Administered tilmicosinc 43 6 49
Administered tylosin tartrated 41 0 41
Administered tylosin phosphatee 0 223 223
aThemajority of cattlewere sampled at both entry into feedlots and after≥60 days
on feed. Entry administration of antimicrobial agents denotesmetaphylactic treat-
ment within 2 days of arrival to feedlots. The ≥60 days on feed administration
of antimicrobial agents denotes therapeutic or subtherapeutic treatment while
placed in feedlots. Antimicrobial administration is shown only for cattle posi-
tive for M. haemolytica and is represented across entry and ≥60 days on feed
samples.
bSubcutaneous (2.5 mg/kg BW). Used for prevention and treatment of BRD.
cSubcutaneous (10 mg/kg BW). Used for prevention and treatment of BRD.
d Subcutaneous (29 mg). Used for preventing abscesses at implant site.
e In feed (11 mg/kg dry matter). Used to prevent liver abscesses.
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Table 4 | Number of cattle and M. haemolytica analyzed by year of the
studya.
Year 1 Year 2 Year 3
Cattle positive for M. haemolytica 403 821 464
Cattle positive for TulR M. haemolytica 0 0 3 (0.6%)
M. haemolytica screened 862 2342 1344
TulR M. haemolytica 0 0 5 (0.4%)
aNumber of cattle is represented across entry and ≥60 days samples. One to
three M. haemolytica isolates per animal were tested.
TulR , tulathromycin-resistant.
Combined, 43% of cattle positive for M. haemolytica at entry
were metaphylactically administered doses of the macrolides
tulathromycin (N = 259), tilmicosin (N = 43), or tylosin tar-
trate (N = 41) within 2 days of arrival (Table 3). Fifty nine cattle
received therapeutic administration of a macrolide during place-
ment, with the majority receiving tulathromycin (N = 53). The
in-feed macrolide tylosin phosphate was administered subthera-
peutically to 223 (13.2%) of the cattle carrying M. haemolytica.
Within the cattle administered tulathromycin, 9 were also treated
with tilmicosin and 45 were administered tylosin phosphate in
feed (data not shown).
MANNHEIMIA HAEMOLYTICA WITH REDUCED TULATHROMYCIN
SUSCEPTIBILITY
Of the 4,548M. haemolytica isolates tested for reduced susceptibil-
ity to tulathromycin, only ﬁve grew on BHI plates supplemented
with 2 μg/mL of tulathromycin (Table 4). These isolates were
cultured from three cattle housed in the same pen during the
third year of the study (Table 5). Isolates 32A, 32B, and 32C were
cultured from animal A028 and were the only M. haemolytica iso-
lated and stored from this individual. Isolate 50A was cultured
from animal A156. A second isolated from this individual did
not exhibit reduced susceptibility to tulathromycin. Isolate 55A
was cultured from animal A877 and was the only strain recov-
ered from this animal. In all instances, isolates with reduced
susceptibility were obtained from samples collected at ≥60days
on feed, on February 10, 2010. A complete history of antimi-
crobial use for these three individuals is presented in Table 5
with all three having been administered metaphylactic doses of
tulathromycin
CHARACTERIZATION OF MANNHEIMIA HAEMOLYTICA ISOLATES WITH
REDUCED TULATHROMYCIN SUSCEPTIBILITY
The ﬁve M. haemolytic isolates capable of growth on BHI plates
supplemented with 2 μg/mL of tulathromycin were further
characterized for susceptibility against a panel of antimicro-
bial agents (Table 1). Each of the isolates grew in 256 μg/mL
sulphadimethoxine, but failed to grow in 2/38 μg/mL trimetho-
prim/sulfamethoxazole. With the exception of isolate 55A, MICs
were similar among isolates. All isolates were resistant to
neomycin, oxytetracycline, tilmicosin, and tulathromycin. In addi-
tion to these, isolate 55A was also resistant to ampicillin and
penicillin.
Each of the isolates harbored aphA-1 and tet(H), confer-
ring resistance to neomycin and oxytetracycline, respectively
(Figure 1). Isolates 50A and 55A also harbored blaROB−1, which
encodes resistance to ampicillin and penicillin, even though only
55A exhibited phenotypic resistance to these antibiotics. None of
themacrolide resistance genes that were screened forwere detected
by PCR in any of the isolates.
Table 5 | History of cattle colonized with tulathromycin-resistant M. haemolyticaa.
Animal
number
Days enrolled
in study
M. haemolytica isolated
≥60 days on feed
Antimicrobial use
Antimicrobial (dose administered) Administration
route
Day of
administration
Day of
withdrawal
A028 84 32A, 32B, 32C Tulathromycin (2.5 mg/kg BW)b Subcutaneous 1 -
Chlortetracycline (35 mg/kg diet DM)c In feed 1 84
Chlortetracycline (6 g/head/day)d In feed 1 22
Monensin sodium (25 mg/kg diet DM)e In feed 1 84
A156 82 50A Tulathromycin (2.5 mg/kg BW) Subcutaneous 1 -
Chlortetracycline (35 mg/kg diet DM) In feed 1 82
Monensin sodium (25 mg/kg diet DM) In feed 1 82
A877 86 55A Tulathromycin (2.5 mg/kg BW) Subcutaneous 1 -
Chlortetracycline (35 mg/kg diet DM) In feed 1 86
Monensin sodium (25 mg/kg diet DM) In feed 1 86
aAll cattle were housed in the same pen and sampled on February 10, 2010.
bUsed for prevention of BRD.
cUsed to prevent liver abscesses.
dUsed to prevent Histophilus somni infection.
eUsed to promote growth and control coccidiosis.
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FIGURE 1 | Genetic relatedness and resistance profiles of tulathromycin-
resistant Mannheimia haemolytica collected from feedlot cattle.The
dendrogram was created using UPGMA clustering of Dice coefﬁcient
values. Similarity matrix was based on band-matching analysis, optimization
and tolerance settings of 1.0 and 1.5%, respectively. Resistance
genotype was based on detection of resistance genes by PCR. Neo,
neomycin; Oxy, oxytetracycline; Til, tilmicosin; Tul, tulathromycin, Amp,
ampicillin.
All ﬁve M. haemolytica isolates were serotype 1. Upon PFGE
analysis, a dendrogram of the isolates revealed two clusters
(Figure 1). Isolates 32A, 32B, and 32C originating from animal
A028 exhibited identical pulsotypes forming one cluster whereas
isolates 50A and 55A from animals A156 and A877 had similar
pulsotypes and formed a second cluster.
DISCUSSION
Across the four feedlots, the prevalence of M. haemolytica car-
riage at entry (13.7%) was similar to previous studies that sampled
healthy feedlot cattle (Klima et al., 2011; Fulton et al., 2002). Only
146 cattle were positive for M. haemolytica at both samplings and
a large number of cattle initially positive at entry became negative
at ≥60days of feed. Despite this, overall prevalence increased at
the ≥60 days on feed time point (20.6%). Active colonization of
the nasal mucosa by M. haemolytica has been shown to ﬂuctu-
ate in feedlot cattle (Magwood et al., 1969) and this may explain
why the majority of cattle shedding at entry or ≥60 days on feed
were only positive at one of the sampling times, and not the other.
The tonsillar crypts have been suggested to be a reservoir for M.
haemolytica (Frank and Briggs, 1992) and isolation from the ton-
sils is possible when nasal samples are negative (Frank et al., 1994).
It has been suggested that sampling at the time of entry into
feedlots most accurately reﬂects the frequency of M. haemolyt-
ica colonization, due to increased shedding resulting from stress
associated with transportation (Frank and Smith, 1983). Our data
suggest that this may not be the case and that a large number
of cattle can actively shed M. haemolytica after ≥60 days in the
feedlot.
Studies on antimicrobial use and development of resistance
in bacteria from livestock have focussed mainly on the potential
impact on human health (Marshall and Levy, 2011). Resistance in
veterinary pathogens has received less attention, despite the impli-
cations not only for animal health and welfare but also for the
increased use of antimicrobial agents as a result of failed therapy.
Given the few antimicrobial agents available to treat BRD (Portis
et al., 2012), it is important to monitor the effect of commer-
cial practices on resistance in BRD-related bacteria including M.
haemolytica.
Metaphylactic treatment of cattle at high-risk of developing
BRD upon feedlot entry has shown efﬁcacy in reducing the rates
of BRD (Taylor et al., 2010). Effective products include ceftiofur,
ﬂorfenicol, tulathromycin, and tilmicosin (Taylor et al., 2010).
Tulathromycin was approved for use in Canada in 2006 to treat
and prevent BRD in feedlot cattle (Schunicht et al., 2007) and was
accordingly beingusedby the feedlots enrolled in thepresent study.
Sampling of cattle was random and took place over a 3-year period
shortly after the approval of tulathromycin. Our study therefore
represents a baseline of tulathromycin susceptibility in the BRD
pathogen M. haemolytica in the feedlots analyzed.
More than 99% of M. haemolytica were susceptible to a
tulathromycin concentration of 2 μg/mL, which is several mag-
nitudes less than the resistant breakpoint (64 μg/mL). Five
isolates were capable of growing on BHI plates supplemented
with 2 μg/mL tulathromycin and each of these isolates were later
conﬁrmed as tulathromycin-resistant, having MICs of 64 μg/mL.
We selected a concentration of 2 μg/mL for screening isolates
with reduced tulathromycin susceptibility based on one of the few
studies that have reported tulathromycin MICs in M. haemolyt-
ica ﬁeld isolates in Europe (Godinho, 2008). Regulations in the
European Union allow for tulathromycin to be used to prevent
BRD, though unlike prevention in Canada, only after conﬁr-
mation of the disease in a herd has been established (European
Medicines Agency, 2013). Similar to our study, Godinho (2008)
reported that low levels (97%) of bovine M. haemolytica ﬁeld iso-
lates had tulathromycin MICs of ≤2 μg/mL and a narrow range of
MICs.
Of the 1,688 individual cattle positive for M. haemolytica,
18.5, 2.9, and 2.4% were administered therapeutic concentra-
tions of tulathromycin, tilmicosin, or tylosin tartrate, respectively.
In addition, 13.2% were administered subtherapeutic concentra-
tions of tylosin phosphate in feed. We included in our analyses all
macrolides commonly used in feedlot production because some
tulathromycin resistance genes have also been shown to con-
fer resistance to tilmicosin and tylosin (Rose et al., 2012) and
increase the MICs of tildipirosin and gamithromycin (Michael
et al., 2012a). Theoretically, tilmicosin and tylosin could have
therefore exerted a selection pressure for tulathromycin resis-
tance. Our study found no evidence for this relationship, as
tulathromycin-resistant M. haemolytica were only isolated from
three cattle. While it is interesting to note that all three of these
animals received metaphylactic doses of tulathromycin and that
resistant M. haemolytica were isolated only at ≥60 days on feed,
these remarkably low rates of resistance do not support any
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association between macrolide use and tulathromycin resistance.
It appeared that the antimicrobial administration practices used
by commercial feedlots in the present study did not select for
tulathromycin resistance over 3 years of sampling. This is sup-
portedby a study thatmeasurednodetectable changes in resistance
in M. haemolytica from feedlot cattle 28 days after therapeutic
administration of tulathromycin and tilmicosin, or subtherapeutic
administration (in-feed) of tylosin (Zaheer et al., 2013).
We focussed only on tulathromycin resistance owing to its rapid
adoption by industry and the opportunity to measure changes in
resistance after introduction of a new antimicrobial prescribed
for metaphylactic and therapeutic use in feedlot cattle. The per-
cent of tulathromycin-resistant M. haemolytica increased from 0%
in year one to 0.4% in year three of our study. Tulathromycin-
resistant M. haemolytica were only detected in the third year, and
this corresponds to 4 years after the approval of tulathromycin in
Canada (Health Canada, 2006). Few other studies have reported
on temporal antimicrobial susceptibility in M. haemolytica since
the approval of tulathromycin for preventing or treating BRD.
Over a similar 3-year timeframe, the German national monitor-
ing program GERM-VET reported an increase in tulathromycin
resistance in M. haemolytica from undetectable in 2004/2005 in
131 isolates examined, to 2% of 55 isolates that were tested in
2006/2007 (BVL, 2011). A comprehensive study analyzed resis-
tance in M. haemolytica isolated from diseased or deceased cattle
that were processed from 24 veterinary diagnostic labs across the
United States and Canada (Portis et al., 2012). More than 300
isolates per year for the years 2004 through 2009 were analyzed.
The authors identiﬁed tulathromycin-resistant M. haemolytica in
2004, the year before the drug was approved for use in the United
States and 2 years before approval in Canada. The reported per-
centages of resistant isolates were 1.8, 2.4, 7.1, 10.7, 9.5, and 8.9
from years 2004–2009, respectively. The large increase in resis-
tance after the introduction of tulathromycin is in contrast to
our study. This difference likely reﬂects the population of ani-
mals used in the two studies. The study by Portis et al. (2012),
included sick and diseased animals whereas our study was a
random sample of primarily healthy cattle in feedlots. There is
strong evidence to suggest that M. haemolytica serotypes 1 and
6 are most frequently associated with BRD (Rice et al., 2008),
and also carry the majority of antimicrobial resistance determi-
nants within the M. haemolytica population (Katsuda et al., 2013;
Klima et al., 2013). Reasons for this are unclear but may be related
to increased antimicrobial use in morbid animals infected with
serotypes 1 and 6, and thus increased resistance in these par-
ticular serotypes. In a recent study however, no M. haemolytica
(N = 41) isolated from cattle diagnosed with BRD in south-
ern Alberta from 2007 to 2008 were resistant to tulathromycin
(Klima et al., 2013). The differences in these studies are difﬁ-
cult to explain but may also be affected by geography or feedlot
management.
Each of the tulathromycin-resistant M. haemolytica isolates
were serotype 1 and multi-drug resistant. This supports previ-
ous observations that multidrug resistance is more likely to occur
in serotype 1 isolates in Canadian feedlots (Klima et al., 2011,
2013). Only two pulsotypes were observed in the bacteria, with all
strains being closely related and having a maximum of three bands
difference in restriction patterns (Tenover et al., 1995; Figure 1).
Three of the isolates (32A, 32B, 32C) originated from a single ani-
mal and appeared to be clones. Isolates 50A and 55Awere collected
from separate cattle, but also appeared to be clonal, having iden-
tical pulsotypes. The animals carrying isolates 50A and 55A were
housed in the same pen and it is possible that transmission of the
strain occurred between these two individuals while in the feed-
lot. Horizontal transfer of M. haemolytica between cattle in beef
operations has previously been reported (Briggs et al., 1998; Timsit
et al., 2013). In addition to tulathromycin, each isolate was resis-
tant to neomycin, oxytetracycline, and tilmicosin and all possessed
genes conferring resistance to neomycin (aphA-1) and oxytetracy-
cline (tet(H)). Oxytetracycline and neomycin resistances are the
most common types of resistance in M. haemolytica in Canadian
feedlots (Klima et al., 2011). Isolates 55A and 50A also encoded
blaROB−1, conferring resistance to penicillin and ampicillin how-
ever only 55A was resistant to these β-lactams. This implies that
isolate 50A somehow lost functionality for ampicillin resistance,
despite having a resistant genotype. None of the isolates carried
any of the macrolide resistance genes that were tested.
The genes erm(42) and msr(E)-mph(E) confer macrolide-
lincosamide and macrolide-triamilide resistance, respectively
(Kadlec et al., 2011). They have been identiﬁed as part of the
integrative conjugative element ICEPmu1 in Pasteurella multocida
(Michael et al., 2012b) andhave been shown to conjugatively trans-
fer from P. multocida to M. haemolytica (Michael et al., 2012c).
Recently, erm(42) and msr(E)-mph(E) have been identiﬁed in M.
haemolytica isolates collected from cattle in the United States and
appear to have been acquired from other members of Pasteurel-
laceae (Desmolaize et al., 2011). We have also observed the same
genes on mobile genetic elements in M. haemolytica isolated from
deceased cattle in the United States (Klima et al., 2013). Their
absence in any of the isolates of the current study could again be
due to geographical differences or the population of cattle investi-
gated. No other genes have yet been reported to confer macrolide
resistance in M. haemolytica. The isolates in our study may encode
a novel tulathromycin resistance gene. We are currently in the
process of sequencing the genomes of these isolates to explore this
possibility. With the isolates being closely related, it is likely that
the resistance element was only recently acquired. Clonal expan-
sion of ﬂuoroquinolone-resistant M. haemolytica amongst cattle
with BRD has been observed (Katsuda et al., 2009). Regardless,
expansion of tulathromycin-resistant M. haemolytica in the feed-
lots we analyzed seemed limited, due to the infrequent observation
of this resistant phenotype.
In conclusion, the current study showed that tulathromycin
resistance in M. haemolytica from a general population of feed-
lot cattle in western Canada was exceptionally low even after this
antibiotic had been used in the industry for a period of 4 years.
There was no evidence that the commercial practices used by
the feedlots in this study selected for tulathromycin-resistant M.
haemolytica. However, resistance has been observed to increase in
isolates from morbid or deceased cattle. These differences may be
due to geography, commercial practices, or the repeated antimi-
crobial treatment of morbid cattle. Future research should include
healthy cattle and those diagnosed with BRD from the same
feedlots to better understand selection of resistant M. haemolytica.
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